The FDA has approved the drug in combination with the standard first-line chemotherapy for endometrial cancer – carboplatin and paclitaxel – with Jemperli used on its own thereafter.

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for Jemperli for the treatment of patients with locally advanced mismatch ...